ReviewCurrent psychiatry reports2003
The genetics of sensory gating deficits in schizophrenia.
Review in Current psychiatry reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.
- Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2017Pooled it
- P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.Schizophrenia bulletin · 2013Trial
- The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine.Neuroscience · 2011Trial
- Timing is everything: neural response dynamics during syllable processing and its relation to higher-order cognition in schizophrenia and healthy comparison subjects.International journal of psychophysiology : official journal of the International Organization of Psychophysiology · 2010Trial
- Review
- Somatosensory gating is related to behavioral and verbal outcomes in children with mild-to-severe hearing loss.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- The Human-Restricted Isoform of the α7 nAChR, CHRFAM7A: A Double-Edged Sword in Neurological and Inflammatory Disorders.International journal of molecular sciences · 2022Review
- α7 nicotinic acetylcholine receptors in the hippocampal circuit: taming complexity.Trends in neurosciences · 2022Review
- Schizophrenia, Bipolar Disorder and Pre-Attentional Inhibitory Deficits.Neuropsychiatric disease and treatment · 2022Review
- Prepulse Inhibition and P50 Suppression in Relation to Creativity and Attention: Dispersed Attention Beneficial to Quantitative but Not Qualitative Measures of Divergent Thinking.Frontiers in psychiatry · 2022Article
- Mechanisms of Nicotine Addiction.Cold Spring Harbor perspectives in medicine · 2021Review
- α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.Neuropharmacology · 2020Review
- iPSC model of CHRFAM7A effect on α7 nicotinic acetylcholine receptor function in the human context.Translational psychiatry · 2019Article
- Current Concepts and Treatments of Schizophrenia.Molecules (Basel, Switzerland) · 2018Review
- Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine.Biochemical pharmacology · 2018Article
- MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating.Human brain mapping · 2017Article
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.International journal of molecular sciences · 2017Review
- New drug developments in psychosis: Challenges, opportunities and strategies.Progress in neurobiology · 2017Review
- Theranostic Biomarkers for Schizophrenia.International journal of molecular sciences · 2017Review
- Dose-Dependent Changes in Auditory Sensory Gating in the Prefrontal Cortex of the Cynomolgus Monkey.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sensory gating abnormalities are an early clinical symptom of schizophrenia, and are characterized by a decrease in the brain's normal ability to inhibit the response to unimportant stimuli. Patients appear hypervigilant and have difficulty focusing their attention. A neurobiologic mechanism involved in these difficulties is nicotinic cholinergic modulation of inhibitory neuronal activity in the hippocampus. One measure of sensory gating abnormalities, diminished inhibition of the P50 evoked response to repeated auditory stimuli, has been linked to the chromosome 15q14 locus of the alpha-7-nicotinic receptor gene. This site is one of several that have shown evidence for linkage to schizophrenia, as well as to bipolar disorder, across several studies. Polymorphisms in the core promoter of the gene are associated with schizophrenia and also with diminished inhibition of the P50 response. These genetic data may identify a new pathophysiologic target for drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.